NEW YORK, Jan. 5 (GenomeWeb News) - Alnylam has granted Dharmacon a non-exclusive license to its Kreutzer-Limmer patent family, enabling the Fisher unit to develop and sell certain RNAi research products and services covered by the patents, Alnylam said today.
The Kreutzer-Limmer family, owned by Alnylam, covers small interfering RNAs and their use to mediate RNAi in mammalian cells. Dharmacon is currently a provider of siRNA reagents, and the Alnylam IP expands its portfolio of internally developed and in-licensed RNAi intellectual property.
Alnylam obtained the rights to the Kreutzer-Limmer patent family, which were awarded in Europe, when it acquired Ribopharma in July 2003. That company is now known as Alnylam Europe. The patent family includes EP Patent No. 1144623, which covers siRNAs up to 25 nucleotides in length having a sequence complementary to a target gene; and EP Patent No. 1214945, which covers compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides.
Patents corresponding to these patents have been issued or are pending in many other countries, Alnylam said.